> top > docs > PubMed:28262346 > annotations

PubMed:28262346 JSONTXT

Annnotations TAB JSON ListView MergeView

GoldHamster

Id Subject Object Predicate Lexical cue
T1 25-44 D001281 denotes atrial fibrillation
T2 25-44 D001281 denotes atrial fibrillation
T6 48-58 1649480 denotes ivabradine
T3 48-58 CHEBI:85966 denotes ivabradine
T4 48-58 CHEBI:85969 denotes ivabradine
T5 48-58 D000077550 denotes ivabradine
T7 48-58 D000077550 denotes ivabradine
T8 92-96 CHEBI:23888 denotes drug
T12 110-120 1649480 denotes Ivabradine
T9 110-120 CHEBI:85966 denotes Ivabradine
T10 110-120 CHEBI:85969 denotes Ivabradine
T11 110-120 D000077550 denotes Ivabradine
T13 110-120 D000077550 denotes Ivabradine
T14 127-136 CHEBI:35222 denotes inhibitor
T15 204-217 D006333 denotes heart failure
T16 204-217 D006333 denotes heart failure
T17 316-335 D001281 denotes atrial fibrillation
T18 316-335 D001281 denotes atrial fibrillation
T19 350-353 1481724 denotes AND
T21 378-384 813859 denotes rabbit
T20 378-384 D011817 denotes rabbit
T22 378-384 9986 denotes rabbit
T24 552-565 194 denotes acetylcholine
T23 552-565 D000109 denotes acetylcholine
T25 552-565 CHEBI:15355 denotes acetylcholine
T26 552-565 D000109 denotes acetylcholine
T27 570-583 6054 denotes isoproterenol
T28 570-583 D007545 denotes isoproterenol
T29 570-583 D007545 denotes isoproterenol
T30 570-583 CHEBI:64317 denotes isoproterenol
T31 570-583 CHEBI:6257 denotes isoproterenol
T32 634-650 GO:0001508 denotes action potential
T33 690-706 GO:0001508 denotes action potential
T38 843-856 6054 denotes isoproterenol
T39 843-856 D007545 denotes isoproterenol
T40 843-856 D007545 denotes isoproterenol
T41 843-856 CHEBI:64317 denotes isoproterenol
T42 843-856 CHEBI:6257 denotes isoproterenol
T50 978-988 1649480 denotes ivabradine
T47 978-988 CHEBI:85966 denotes ivabradine
T48 978-988 CHEBI:85969 denotes ivabradine
T49 978-988 D000077550 denotes ivabradine
T51 978-988 D000077550 denotes ivabradine
T57 1016-1025 MOP:0000569 denotes reduction
T58 1029-1034 PR:O35889 denotes AF (6
T59 1029-1034 PR:P55196 denotes AF (6
T60 1029-1034 PR:Q9QZQ1 denotes AF (6
T62 1029-1034 PR:000010453 denotes AF (6
T61 1029-1034 CVCL_U801 denotes AF (6
T66 1063-1073 1649480 denotes Ivabradine
T63 1063-1073 CHEBI:85966 denotes Ivabradine
T64 1063-1073 CHEBI:85969 denotes Ivabradine
T65 1063-1073 D000077550 denotes Ivabradine
T67 1063-1073 D000077550 denotes Ivabradine
T69 1304-1311 D011817 denotes rabbits
T70 1304-1311 9986 denotes rabbits
T74 1325-1335 4441 denotes flecainide
T71 1325-1335 D005424 denotes flecainide
T72 1325-1335 CHEBI:75984 denotes flecainide
T73 1325-1335 D005424 denotes flecainide
T78 1337-1347 4441 denotes Flecainide
T75 1337-1347 D005424 denotes Flecainide
T76 1337-1347 CHEBI:75984 denotes Flecainide
T77 1337-1347 D005424 denotes Flecainide
T79 1509-1513 UBERON:0008338 denotes sole
T81 1529-1542 194 denotes acetylcholine
T80 1529-1542 D000109 denotes acetylcholine
T82 1529-1542 CHEBI:15355 denotes acetylcholine
T83 1529-1542 D000109 denotes acetylcholine
T84 1547-1560 6054 denotes isoproterenol
T85 1547-1560 D007545 denotes isoproterenol
T86 1547-1560 D007545 denotes isoproterenol
T87 1547-1560 CHEBI:64317 denotes isoproterenol
T88 1547-1560 CHEBI:6257 denotes isoproterenol
T92 1642-1652 1649480 denotes ivabradine
T89 1642-1652 CHEBI:85966 denotes ivabradine
T90 1642-1652 CHEBI:85969 denotes ivabradine
T91 1642-1652 D000077550 denotes ivabradine
T93 1642-1652 D000077550 denotes ivabradine
T97 1826-1836 4441 denotes flecainide
T94 1826-1836 D005424 denotes flecainide
T95 1826-1836 CHEBI:75984 denotes flecainide
T96 1826-1836 D005424 denotes flecainide

PubMed_Structured_Abstracts

Id Subject Object Predicate Lexical cue
T1 110-341 BACKGROUND denotes Ivabradine is an inhibitor of mixed Na(+)-K(+)-currents and routinely administered in chronic heart failure. Clinical studies reported divergent trends regarding proarrhythmic and antiarrhythmic effects in atrial fibrillation (AF).
T2 363-1576 RESULTS denotes In 12 isolated rabbit hearts AF was induced in 7 of 12 hearts (13 episodes) under baseline conditions by a standardized protocol employing atrial burst pacing. Thereafter, a combination of acetylcholine and isoproterenol was employed to enhance AF occurrence. Monophasic action potential recordings showed a decrease of atrial action potential duration (aAPD,-37ms, p<0.05) and atrial effective refractory period (aERP;-39ms, p<0.05) after infusion of both acetycholine (1μM) and isoproterenol (1μM) as compared with baseline. This led to induction of AF in 11 of 12 hearts (124 episodes). Simultaneous infusion of ivabradine (3μM) led to a significant reduction of AF (6 of 11 hearts, 63 episodes). Ivabradine induced an increase of aAPD (+9ms) and aERP (+30ms, p<0.05) leading to a marked increase of atrial post-repolarization refractoriness (aPRR), defined as the difference of aERP and aAPD (+21ms, p<0.05). Results were compared to 10 rabbits treated with flecainide. Flecainide treatment also induced a significant increase of aPRR and resulted in induction of AF in 6 of 10 hearts (58 episodes) while 9 of 10 hearts were inducible during sole treatment with acetylcholine and isoproterenol (129 episodes).
T3 1589-1837 CONCLUSIONS denotes In the present experimental study, administration of ivabradine reduced inducibility of AF and therefore may represent a supplemental therapeutic option in AF. Of note, its antiarrhythmic efficacy was comparable to the established agent flecainide.

Goldhamster2_Cellosaurus

Id Subject Object Predicate Lexical cue
T1 77-79 CVCL_8754|Cancer_cell_line|Homo sapiens denotes an
T2 77-79 CVCL_H241|Cancer_cell_line|Homo sapiens denotes an
T3 124-126 CVCL_8754|Cancer_cell_line|Homo sapiens denotes an
T4 124-126 CVCL_H241|Cancer_cell_line|Homo sapiens denotes an
T5 146-148 CVCL_7082|Cancer_cell_line|Homo sapiens denotes Na
T6 412-417 CVCL_S732|Cancer_cell_line|Homo sapiens denotes of 12
T7 468-469 CVCL_6479|Finite_cell_line|Mus musculus denotes a
T8 535-536 CVCL_6479|Finite_cell_line|Mus musculus denotes a
T9 669-670 CVCL_6479|Finite_cell_line|Mus musculus denotes a
T10 921-923 CVCL_5986|Cancer_cell_line|Homo sapiens denotes 11
T11 924-929 CVCL_S732|Cancer_cell_line|Homo sapiens denotes of 12
T12 1002-1003 CVCL_6479|Finite_cell_line|Mus musculus denotes a
T13 1038-1040 CVCL_5986|Cancer_cell_line|Homo sapiens denotes 11
T14 1049-1051 CVCL_W174|Factor-dependent_cell_line|Mus musculus denotes 63
T15 1082-1084 CVCL_8754|Cancer_cell_line|Homo sapiens denotes an
T16 1082-1084 CVCL_H241|Cancer_cell_line|Homo sapiens denotes an
T17 1145-1146 CVCL_6479|Finite_cell_line|Mus musculus denotes a
T18 1371-1372 CVCL_6479|Finite_cell_line|Mus musculus denotes a
T19 1437-1444 CVCL_UM80|Cancer_cell_line|Homo sapiens denotes 6 of 10
T20 1453-1455 CVCL_2564|Transformed_cell_line|Homo sapiens denotes 58
T21 1694-1697 CVCL_E773|Transformed_cell_line|Homo sapiens denotes may
T22 1708-1709 CVCL_6479|Finite_cell_line|Mus musculus denotes a